Principles of care for acquired hemophilia

Gerry Dolan1 | Gary Benson2 | Annette Bowyer3 | Hermann Eichler4 | Cedric Hermans5 | Victor Jiménez-Yuste6 | Rolf Ljung7 | Debra Pollard8 | Elena Santagostino9 | Silva Zupančić Šalek10

1Centre for Haemostasis and Thrombosis, St Thomas’ Hospital, London, UK
2Haemophilia and Thrombosis Centre, Belfast City Hospital, Belfast, Northern Ireland
3Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
4Institute of Clinical Haemostaseology and Transfusion Medicine, University and University Hospital of the Saarland, Homburg, Germany
5Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium
6Hospital Universitario La Paz, Unidad de Coagulopatias, Servicio de Hematología, Autonoma University, Madrid, Spain
7Department of Clinical Sciences – Pediatrics, Lund University, Lund, Sweden
8Katharine Dormandy Haemophilia & Thrombosis Centre, Royal Free London NHS Foundation Trust, London, UK
9Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Anglo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
10University Hospital Centre Zagreb, School of Medicine, University of Osijek and Medical School University of Zagreb, Croatia

Abstract
Objective: To establish clear priorities for the care of patients with acquired hemophilia A (AHA) by proposing 10 key principles of practical, holistic AHA management.

Method: These principles were developed by the Zürich Haemophilia Forum, an expert panel of European hemophilia specialists comprising physicians and nursing and laboratory specialists.

Results: The 10 proposed principles for AHA care are as follows: (a) Improving initial diagnosis of AHA; (b) Differential diagnosis of AHA: laboratory assessment of patients with unusual bleeding; (c) Effective communication between laboratories, physicians, and specialists; (d) Improving clinical care: networking between healthcare professionals in the treating hospital and specialist hemophilia centers; (e) Comprehensive assessment of bleeding; (f) Appropriate use of bypassing agents; (g) Long-term follow-up and monitoring for efficacy and safety of immunosuppressive treatment; (h) Inpatient/outpatient settings; (i) Access to innovative and disruptive treatments; (j) Promotion of international collaborative research.

Conclusion: The proposed principles for holistic AHA care aim to ensure swift diagnosis and optimal patient management. Key to achieving this goal is training for healthcare personnel in non-specialist hospitals and collaboration between different specialists. We hope these principles will increase awareness of AHA in the wider medical community and catalyze efforts toward improving its practical, multidisciplinary management.

KEYWORDS acquired hemophilia, care, diagnosis, management, principles, treatment

1. What is the new aspect of your work?
We offer ten key principles for the practical and holistic management of individuals with acquired hemophilia A (AHA) care. The aim is to guide patient management from first presentation that often occurs outside specialist hematology settings, through to treatment and follow-up.

2. What is the central finding of your work?
The timely diagnosis and effective management of AHA depend on a multidisciplinary approach founded on two key factors: educating healthcare personnel in smaller, non-specialist...
settings about this rare disorder; and establishing good communication and collaboration between hemophilia specialists and the wide-ranging healthcare professionals involved in the patient pathways.

3. What is (or could be) the specific clinical relevance of your work?

It is hoped that the 10 proposed principles will improve awareness of AHA in the wider medical community, help to ensure swifter diagnosis and more effective management of AHA, and act as a catalyst for further research and collaborative investment in the practical, multidisciplinary management of AHA.

**TABLE 1** Principles of acquired hemophilia A care

| Principle | Improving initial diagnosis of AHA in all settings |
|-----------|---------------------------------------------------|
| Principle 2 | Differential diagnosis of AHA: Laboratory assessment of patients with unusual bleeding |
| Principle 3 | Effective communication between laboratories, physicians, and specialists |
| Principle 4 | Improving clinical care: networking between HCPs in the treating hospital and specialist hemophilia treatment centers |
| Principle 5 | Comprehensive assessment of bleeding is required |
| Principle 6 | Appropriate use of bypassing agents for prompt treatment |
| Principle 7 | Long-term follow-up and monitoring for efficacy and safety of immunosuppressive treatment |
| Principle 8 | Promotion of patient care and follow-up in the home, inpatient and outpatient settings |
| Principle 9 | Access to innovative and disruptive treatments will be important |
| Principle 10 | Promotion of collaborative research to improve patient outcomes |

Abbreviations: AHA, acquired hemophilia A; HCP, healthcare professionals.
3 | PRINCIPLES OF ACQUIRED HEMOPHILIA CARE

3.1 | Principle 1: Improving initial diagnosis of AHA in all settings

3.1.1 | Rationale

- The rarity of AHA, combined with its heterogeneous bleeding phenotype and association with advanced age and multiple co-morbidities, means that diagnosis can be challenging.

- This difficulty is compounded by the low awareness of AHA in the wider medical community. This is problematic, as patients with AHA typically present to a wide range of clinical teams (eg, internal medicine, emergency, or intensive care physicians; geriatricians; obstetricians; rheumatologists; oncolgists; or surgeons).

- Lack of familiarity with AHA may mean that patients are not referred to the correct specialist care, or that they remain undiagnosed. Thus, it is likely that AHA will be frequently under- or misdiagnosed and inadequately treated in real-world clinical practice.

3.1.2 | Improving recognition of AHA

AHA is extremely rare, affecting approximately 1.5 individuals per million population per year. Even specialists within hemophilia treatment centers (HTCs), such as those in this panel, only see a few cases per year, and suspected cases of AHA that present outside of these specialist centers are not systematically referred to experts in HTCs. Further, the bleeding pattern in AHA is heterogeneous: It is typically characterized by subcutaneous bleeds, bleeding into other soft tissues or mucous membranes, and muscle hematomas, and bleeds may range from mild enough that they do not require treatment to so severe that they threaten life, limbs, or organs (Figure 1). Additionally, although 50% of AHA cases are associated with underlying medical conditions, including autoimmune disease, malignancy, infections, postpartum, and drug-related conditions, the remaining 50% are idiopathic.

Recognizing AHA can therefore be extremely difficult. Nonetheless, some diagnostic indicators can be proposed. When faced with unexpected bleeding in older males and females or in postpartum women in the absence of a personal or family history of bleeding, physicians should first evaluate the patient’s medical history, including current medication use. If the effects of anticoagulant therapy can be ruled out as the cause of bleeding, physicians should suspect AHA and investigate accordingly. It should be noted, however, that AHA may develop in individuals already on anticoagulant therapy. Although AHA predominantly affects elderly individuals and postpartum women, it can also occur in patients of any age with malignancy or autoimmune disease; therefore, unexpected bleeding in these patients should also be investigated. The first step to confirming a diagnosis of AHA is a thorough laboratory investigation (see Section 3.2: Principle 2).

3.1.3 | Improving awareness in the wider medical community

Increasing awareness of AHA among the wider medical community will improve recognition of AHA and ultimately improve patient outcomes. Multiple and varied initiatives should be considered in the attempt to improve awareness, including awareness campaigns, webinars, scientific meetings, leaflets, brochures, training programs, networking events, dedicated sessions on AHA at national and international conferences, and the publication of recommendations and other relevant articles in general medicine journals with open access.

Efforts to improve awareness of AHA among specialists in other, non-hemophilia fields should position AHA as a medical emergency, as well as highlight its clinical presentation and bleeding phenotype and differentiate it from congenital hemophilia (Table 2).
**Key takeaway**
Increasing awareness of AHA in the wider medical community will aid recognition of the disease, facilitate patient referral to specialist care, and ultimately improve outcomes.

**3.2 | Principle 2: Differential diagnosis of AHA: Laboratory assessment of patients with unusual bleeding**

**3.2.1 | Rationale**
- An isolated, prolonged activated partial thromboplastin time (aPTT) is often the first clue and recognition of this feature is key to diagnosing AHA.

**3.2.2 | Laboratory investigation**
The finding of a low FVIII coagulant activity (FVIII:C) is crucial in the diagnosis of AHA. Thereafter confirmatory tests to demonstrate the antibody-mediated or inhibitory activity against FVIII will establish the diagnosis. Several diagnostic algorithms have been proposed to confirm AHA (see, for example, Collins et al,1 Kruse-Jarres et al,1 Tiede et al16); an overview of key diagnostic steps is provided in Figure 2.

It is important for smaller hospitals and laboratories in non-hematology specialist centers to establish a strategy for dealing

---

**TABLE 2 Advice for non-specialists: improving awareness, diagnosis, and treatment of AHA outside specialist centers**

| Diagnosing AHA | Laboratory investigation |
|----------------|-------------------------|
| **Awareness of the following features of AHA will aid recognition of the disease and facilitate referral of patients to specialist centers:** | • If the effects of anticoagulant therapy can be ruled out as the cause of bleeding in a patient with unexpected hemorrhaging and no bleeding history, physicians should suspect AHA and investigate accordingly. |
| • AHA is an acquired autoimmune disease that typically develops in middle age and beyond. Therefore, patients are typically older, with higher rates found in males.8,47 However, there is also a smaller peak in incidence among younger women (aged 20-40 years) that is associated with pregnancy.8 | • An isolated, prolonged aPTT with a normal PT is usually the first indicator of AHA, even in patients without bleeding, and should always be investigated.1,3,6,16 Investigating an unusual aPTT should be prioritized along with (or even over) determining the site of bleeding.49 |
| • Individuals who develop AHA have no previous or family history of bleeding3,5,6; therefore, a lack of bleeding history does not rule out AHA. However, anticoagulant use is a frequent cause of bleeding in elderly individuals and should be ruled out. | • However, a prolonged aPTT may also be caused by coagulation factor deficiencies, von Willebrand disease, lupus anticoagulant, or therapy with anticoagulants3,6,16; therefore, a differential diagnosis of AHA must be generated. |
| • While joint bleeds are a hallmark of congenital hemophilia, they are rare in AHA.3,47,48 Therefore, an absence of joint bleeds does not rule out AHA. Instead, the bleeding pattern in AHA is characterized predominantly by subcutaneous bleeds, bleeding into other soft tissues or mucous membranes, and muscle hematomas3,5,8,11 | • In cases where there is a prolonged aPTT but it is difficult to generate a differential diagnosis, the prolonged aPTT results and details of bleeding should be referred to a hematology specialist. |
| • Bleeds can be severe (life, limb, or organ threatening) or mild enough that treatment is not needed.5,6,8,11,14 | Patient management: advice for nurses |
| • AHA is commonly associated with autoimmune disease, malignancy, infections, and drug-related conditions.5,8,11,15 | • Examine the condition and integrity of the skin regularly and report any new appearances of bruising or skin breakdown to the hemophilia/hematology team immediately to aid monitoring of the bleeding episode and treatment decisions. |
| |
| **Laboratory investigation** | • Bleeds for which hemostatic treatment has been initiated should be frequently monitored to evaluate treatment efficacy. |
| • An isolated, prolonged aPTT with a normal PT is usually the first indicator of AHA, even in patients without bleeding, and should always be investigated.1,3,6,16 Investigating an unusual aPTT should be prioritized along with (or even over) determining the site of bleeding.49 | • Where possible, avoid manual handling and use mechanical aids instead. |
| • However, a prolonged aPTT may also be caused by coagulation factor deficiencies, von Willebrand disease, lupus anticoagulant, or therapy with anticoagulants3,6,16; therefore, a differential diagnosis of AHA must be generated. | • Avoid non-essential medical and nursing interventions that carry a bleeding risk. |
| • In cases where there is a prolonged aPTT but it is difficult to generate a differential diagnosis, the prolonged aPTT | • Avoid continuous electronic blood pressure monitoring, unless indicated by a clinically deteriorating condition. |
| results and details of bleeding should be referred to a hematology specialist. | • Use caution if venipuncture/cannulation is required; central venous access devices may be considered instead. Central venous catheter insertions must be performed with hemostatic coverage. |
| |
| **Patient management: advice for nurses** | • Use caution when applying and removing adhesive dressings. |
| • Examine the condition and integrity of the skin regularly and report any new appearances of bruising or skin breakdown to the hemophilia/hematology team immediately to aid monitoring of the bleeding episode and treatment decisions. | • Be aware that home visits and/or patient education may be required to help minimize injury risk in the patient’s home. |
| • Bleeds for which hemostatic treatment has been initiated should be frequently monitored to evaluate treatment efficacy. | • Be alert for signs of infection (which can be fatal in patients receiving immunosuppressive treatment to eradicate the anti-FVIII inhibitor). |

Abbreviations: AHA, acquired hemophilia A; aPTT, activated partial thromboplastin time; FVIII, factor VIII; PT, prothrombin time.
with a prolonged aPTT, especially in cases where discrimination between AHA and other potential causes of a prolonged aPTT is difficult. This strategy should involve referring unexpected prolonged aPTT results and details of any bleeding to a specialist (see Section 3.3: Principle 3). To raise awareness of AHA and the associated diagnostic work-up, more attention should also be given to presenting case studies at laboratory educational initiatives.

**Key takeaway**
AHA should be suspected in patients with unexplained bleeding and a prolonged aPTT.

### 3.3 | Principle 3: Effective communication between laboratories, physicians, and specialists

#### 3.3.1 | Rationale

- Laboratory test results can be confusing and difficult to interpret, especially for non-specialists (see Section 3.2: Principle 2).
- It is crucial to support clinicians in smaller, non-HTC hospitals, and to improve organization, collaboration, and information-sharing between physicians and laboratory scientists.

#### 3.3.2 | How to improve communication

The key to accurate interpretation of laboratory test results and prompt AHA diagnosis is effective communication and collaboration between the laboratory, hemophilia/coagulation specialists, and the physician requesting the tests.

When requesting laboratory tests, physicians should tell the laboratory staff whether or not the patient is actively bleeding and provide comprehensive information regarding the patient’s history, symptoms, and clinical scenario. Physicians should also indicate to whom test results should be returned—time is often wasted in trying to find the clinician who requested the test and the laboratory personnel must be aware that this is an urgent clinical situation and that the processing of tests should be prioritized. In turn, laboratories could better support physicians by providing a written explanation and interpretation of the results, rather than returning the results without comment.

Further, it is important to establish a system that flags changes in aPTT results over time. In the event of abnormal test results, such as a prolonged aPTT, the laboratory could suggest next steps to take, such as contacting the hematology team immediately if further information is needed. It may also be useful for hospitals to define which other clinical and laboratory scenarios trigger a

---

**FIGURE 2** Key steps in diagnosing AHA. AHA, acquired hemophilia A; aPTT, activated partial thromboplastin time; FVIII, factor VIII; FIX, factor IX; FXI, factor XI; FXII, factor XII; HTC, hemophilia treatment center; LA, lupus anticoagulant; VWD, von Willebrand disease; VWF, von Willebrand factor
request for the hematologist to see the patient and/or consult with the patient’s physician.

Key takeaway
The laboratory diagnosis of AHA requires: (a) collaboration and information-sharing between the specialist, the treating physician, and laboratory personnel; and (b) a system by which important changes in laboratory results and/or clinical conditions are flagged up to specialists.

3.4 | Principle 4: Improving clinical care—networking between HCPs in the treating hospital and specialist HTCs

3.4.1 | Rationale
- When a patient with suspected AHA presents in a non-specialist setting, collaboration with hemostasis experts is vital for ensuring accurate diagnosis and optimal management. Therefore, every non-HTC hospital and laboratory should know whom to contact when treating patients with unexplained bleeding.
- Effective networking between HCPs in specialist HTCs and non-specialist hospitals will facilitate the recognition of AHA, swift referral to specialist care, and delivery of effective treatment.
- Patients with AHA are prone to subcutaneous, mucosal, and soft tissue bleeding that can occur after minimal trauma and that can quickly become life threatening. Further, invasive procedures should be avoided unless they are absolutely necessary, in which case they should only be performed under bypassing agent coverage. Therefore, collaboration can also help ensure that patients are handled and managed in a way that minimizes the risk of iatrogenic injury.

3.4.2 | Networking to improve patient care
A key principle of care must include collaboration between HCPs in the treating hospital and those in a specialist HTC. This collaboration needs to begin as soon as a patient is diagnosed and should involve a multidisciplinary approach to ensure effective assessment of bleeding, timely treatment, and appropriate care. The multidisciplinary team responsible for patient care should include hemophilia specialists, physiotherapists, laboratory staff, and other relevant specialists (such as physicians specializing in internal medicine, emergency medicine, geriatrics, obstetrics, rheumatology, and oncology).

Collaboration should include education of relevant staff. For example, specialist nurses in HTCs should provide training and education to nurses and key staff in non-specialist centers about the early recognition of signs and symptoms of bleeds and the need for prompt treatment. Education about appropriate patient handling in order to minimize the risk of inducing bleeds is also important. (Table 2). Individuals with AHA should, where possible, be treated in a specialist environment, however, the treating physician and HTC staff may decide if the patient should remain in the non-specialist HTC (for example, if the patient is too ill to be transferred). In such circumstances, collaboration between the treating staff and their HTC counterparts ensures effective delivery of comprehensive care. Networks of hospitals who collaborate in managing patients with bleeding disorders should also establish counseling programs for such patients, including those with AHA.

Key takeaway
Collaboration with hematology experts and the development of multidisciplinary care teams are vital for the optimal management of patients with AHA.

3.5 | Principle 5: Comprehensive assessment of bleeding is required

3.5.1 | Rationale
- While treatment of acute bleeds is a key priority in AHA care, not all patients bleed, and not all bleeds require intervention.
- Elderly patients with multiple comorbidities—often the case with AHA patients—may face an increased risk of thrombosis during treatment with bypassing agents; therefore, the benefits and disadvantages of initiating hemostatic treatment must be carefully weighed.

3.5.2 | Bleed assessment and rationale for initiating hemostatic treatments
Recent recommendations on hemostatic therapy and treatment evaluation have been published so these aspects are not covered in detail here. Instead, our focus concerns the decision about whether to treat a bleed.

The type of bleed is important when determining whether hemostatic treatment is needed. Generally, retroperitoneal or retropharyngeal hematomas, muscle bleeds, intracranial hemorrhage, severe hematuria, bleeds in multiple sites, and gastrointestinal, pulmonary, or postoperative bleeding all require hemostatic treatment. However, ecchymosis and mild to moderate subcutaneous bleeds may not require hemostatic treatment, and close observation may be sufficient. Bleeds for which treatment has been initiated should also be assessed regularly to evaluate treatment efficacy. The use of a body map can be a useful tool in serial assessment (Figure 3). Treatment is recommended in patients with severe bleeds and/or a significant decrease in hemoglobin levels, irrespective of the inhibitor titer. Additional considerations are also important. First, treatment benefits must be weighed against the risks: for example, the use of bypassing agents may put patients at risk for arterial and venous thromboembolism, particularly in elderly patients and those with predisposing conditions (eg, underlying malignancy or history of thrombosis). Second, severe bleeds may require aggressive treatment; however, surgical removal of hematomas should be avoided.
Key takeaway
It is crucial to know which bleeds and which clinical scenarios require hemostatic intervention, and the benefits of initiating hemostatic treatment must be weighed against the potential risks.

3.6 | Principle 6: Appropriate use of bypassing agents for prompt treatment

3.6.1 | Rationale

- When it has been ascertained that a bleed requires treatment, a key priority in AHA care is to start hemostatic treatment promptly to control bleeding, especially when severe.6,9,15

Use of the body map involves the following steps:

1. Draw any bleeding on body map on admission
2. Draw around bleeds on patient skin to aid monitoring
3. Check patient every shift for new or extended bleeding
4. Report any new or extended bleeding to hemophilia team.

- Bypassing agents (recombinant activated factor VII [rFVIIa; NovoSeven®, Novo Nordisk, Bagsvaerd, Denmark] and plasma-derived activated prothrombin complex concentrate [pd-aPCC; FEIBA, Baxter, Deerfield, IL, USA]) are used as first-line treatment for bleed control.3,6,9 Recombinant porcine FVIII (rpFVIII; Obizur®, Baxalta/Shire) is also available; rpFVIII is similar enough to human FVIII to provide clotting activity in humans, but its lack of complete homology with human FVIII means that it may not be neutralized by inhibitory anti-human FVIII antibodies.20,21 However, experience with rpFVIII in the acute clinical setting is more limited.20-23

- Three key studies support the use of rFVIIa and pd-aPCC in AHA,14,24,25 and similar efficacy between the two agents has been reported.14 However, the feasibility of administering prompt treatment with bypassing agents may be influenced by various practical considerations.

FIGURE 3  Example of a body map for monitoring bleeds in AHA. Use of the body map involves the following steps: (1) Draw any bleeding on body map on admission. (2) Draw around bleeds on patient skin to aid monitoring. (3) Check patient every shift for new or extended bleeding. (4) Report any new or extended bleeding to hemophilia team. AHA, acquired hemophilia A.
3.6.2 | Managing bypassing agent use

First-line treatment for bleed control in patients with AHA may be provided by either rFVIIa, pd-aPCC, or rpFVIII. Recombinant FVIIa is administered at an initial dose of 90 µg/kg, with repeat doses administered every 2-3 hours, if necessary, to control bleeding. A higher initial dose may be required, for example, 270 µg/kg, depending on the clinical situation. FEIBA is generally administered at doses of 50-100 U/kg repeated every 6-12 hours, depending on the location and severity of bleeding. The maximum recommended dose is 200 U/kg/day. The dosing of pFVIII is usually 200 U/kg initially with further dosing depending on plasma levels of pFVIII and the clinical situation. Efficacy may be influenced by anti-porcine FVIII titer.

Administering these bypassing agents may be impacted by several considerations including availability of the therapeutic agent since these are not widely stocked. First, ideally, the patient should be transferred to a facility where these drugs are available. This treating facility should have sufficient availability of trained staff experienced using these drugs and in reconstituting and administering bypassing agents. An additional consideration may be the time required to administer these agents: pd-aPCC, for example, has longer mixing and administration time (30-60 minutes per dose); rFVIIa requires dosing every 2-3 hours until the bleed is controlled. Also, venous access must be assessed, managed, and preserved in patients receiving bypassing agents. A peripherally inserted central catheter (PICC) line can be beneficial: some clinicians prefer to use a PICC line in all patients with AHA who require hospital admission, frequent venous sampling, and intravenous therapy, while others reserve its use for patients with difficult venous access and/or high risk of cutaneous bleeding with further venepuncture (Table 2).

Where rFVIIa is concerned, treatment feasibility might be enhanced by using an infusion pump method designed to deliver timed, accurate bolus doses. However, this novel delivery method is not currently widely available for routine use. For rpFVIII, a validated laboratory assay for monitoring treatment is important.

Regular clinical monitoring of vital signs and site of bleeding is essential to confirm efficacy and switching to an alternative therapy should be considered with suboptimal response. The duration of treatment will depend on the clinical circumstance and as a minimum, treatment should continue until there are no signs of bleeding.

**Key takeaway:**

By-passing agents (rFVIIa and pd-aPCC) and rpFVIII are first-line treatments for bleeds that require intervention; where possible, patients should be transferred to a facility where bypassing agents (and staff trained in their use) are available.

3.7 | Principle 7: Long-term follow-up and monitoring for efficacy and safety of immunosuppressive treatment

3.7.1 | Rationale

- Although the anti-FVIII inhibitor that causes AHA may spontaneously disappear without treatment in ~ 30% of cases, remission occurrence is unpredictable and a patient remains at risk of serious bleeding while the inhibitor persists.
- Therefore, it is currently recommended that all patients with AHA receive immunosuppressive therapy (IST) to eradicate the inhibitor. First-line options for IST include corticosteroids alone or in combination with cyclophosphamide; if initial treatment fails, subsequent attempts with IST might be initiated with other immunosuppressive agents such as azathioprine, vincristine, mycophenolate, cyclosporine, or rituximab.
- However, up to 20% of patients receiving IST experience a relapse and most IST drugs carry potential side effects. Prolonged follow-up for efficacy and safety is therefore required.

3.7.2 | Long-term follow-up for efficacy

Monitoring IST may depend on individual clinical situations and practicability. Current recommendations suggest that patients on IST can be monitored weekly on an outpatient basis during the first 6 weeks of therapy unless there is active bleeding or comorbidities involving hospitalization, surgery, invasive procedures, or delivery. If patients are hospitalized, they should be monitored twice weekly. Routine monitoring should include physical examination, full blood count, aPTT, FVIII activity, and anti-FVIII inhibitor titer; FVIII levels and anti-FVIII inhibitor titers should be monitored until FVIII levels normalize and the inhibitor becomes undetectable although anti-FVIII inhibitor titers may not to be tested as frequently as FVIII:C levels.

After achieving a sustained response, IST can be tapered. Once it has been discontinued completely, monitoring for aPTT and plasma FVIII levels should continue so that any inhibitor recurrence can be detected. It has been suggested that aPTT and FVIII levels should be monitored monthly during the first 6 months after achieving remission, every 2-3 months up to 12 months, and every 6 months during the second year and beyond to assess for relapse. Patients who experience bleeding after successful IST should be carefully evaluated, as such bleeding could indicate inhibitor recurrence.
3.7.3 | Long-term follow-up for safety

IST is associated with high morbidity rates, as most immunosuppressive drugs are associated with frequent complications that can be fatal in this (typically) frail, elderly population.\textsuperscript{1,6,15} Infection (including sepsis) is a common cause of IST-related morbidity and can lead to higher mortality rates than bleeding.\textsuperscript{1,6,10,24,34} Other adverse effects commonly associated with IST include raised blood sugar/worsened diabetes mellitus, psychiatric disorders, and mucous membrane ulcers.\textsuperscript{10,24} Patients should be monitored closely\textsuperscript{1,6} and any signs of infection, sepsis, or high fever of unknown origin should be considered as either contraindications for IST or as grounds for adjusting ongoing treatment. The patient’s age and presence of severe, life-limiting comorbidities should also be considered when making decisions about starting, continuing, or adjusting IST.\textsuperscript{6} Physicians should aim to balance the need for swift inhibitor eradication with the need to minimize exposure to potential side effects.\textsuperscript{6}

**Key takeaway**

Immunosuppressive therapy (IST) to eradicate the inhibitor is recommended for all AHA patients, but regular monitoring is crucial to maintain a balance between rapid inhibitor eradication and minimizing complications, which can be frequent and severe.

### 3.8 | Principle 8: Promotion of patient care and follow-up in the home, inpatient and outpatient settings

#### 3.8.1 | Rationale

- Patients with AHA must be monitored carefully, as the rates of adverse events, morbidity, and mortality are high.\textsuperscript{32} Further, as FVIII:C in AHA is not predictive of bleeding risk, patients can have significant bleeding despite a modest reduction in FVIII:C.\textsuperscript{1,33} It is also crucial to monitor efficacy, response, and side effects associated with hemostatic treatments and IST.\textsuperscript{32}
- However, maintaining patient follow-up for long periods of time can be difficult, especially when frail, elderly patients live at home or in nursing homes and are unable to travel to clinic appointments at the hospital. Strategies to encourage and facilitate such regular monitoring should be devised.

#### 3.8.2 | Patient care and follow-up in the home, inpatient and outpatient settings

Numerous factors affect not only the feasibility but also the location (home or hospital) of long-term patient monitoring and care. Logistics—such as the patient’s geographical location—play a key role. For example, it can be challenging to obtain follow-up samples for measurement of FVIII:C from patients in the community who live at home or in a nursing home and who are unable to travel to clinic appointments at the hospital. For some (but not all) of these patients, it is possible for community nurses or nursing home nurses to facilitate long-term follow-up by obtaining regular blood samples in a timely manner. Other significant factors affecting how and where treatment is monitored and delivered include the availability of facilities and resources, along with the organization and infrastructure of healthcare systems. Thus, whether treatment and monitoring take place in the hospital (in the inpatient/outpatient setting) or in the patient’s home depends on a variety of factors.

Priority should also be given to educating patients about how to recognize bleed symptoms, report them, and urgently access care so that hemostatic treatment can be initiated promptly (see Section 3.6: Principle 6). When a patient has a significant, active bleed that requires treatment, they should be monitored closely in the hospital, and the patient may need to be admitted as an inpatient. It has been recommended that assessment of bleed location and severity should be performed every 6-12 hours\textsuperscript{32}; while it may be unrealistic to see significant changes with such frequent monitoring, we consider 12-hourly monitoring to be helpful for new bleeds in inpatients, some of whom may not advocate well for themselves. As soon as complete remission with normal FVIII:C activity has been achieved, either by AHA treatment or by spontaneous remission, it should be evaluated whether prophylaxis is indicated to prevent venous thromboembolism.

**Key takeaway**

Long-term patient care and monitoring are affected by numerous factors and challenges, including logistics, resource availability, and organization of healthcare systems. Appropriate proactive strategies are required to ensure and facilitate continued care and follow-up.

### 3.9 | Principle 9: Access to innovative and disruptive treatments will be important

#### 3.9.1 | Rationale

- While bypassing agents are the current treatment of choice for managing bleeding in patients with AHA, they are not without clinical shortcomings. For instance, neither is predictably effective;\textsuperscript{35} patients may exhibit differential responses to treatment;\textsuperscript{35,36} treatment cannot be monitored with conventional laboratory assays;\textsuperscript{32} and bypassing agents increase the risk for thromboembolism in elderly patients with comorbidities.\textsuperscript{32,35}

#### 3.9.2 | Emerging and innovative therapies

In the future various new and emerging non-factor therapies may offer treatment options for patients with AHA. To date, no emerging non-factor therapies have been approved for AHA.
Hemlibra® (Emicizumab, Roche, Basel, Switzerland) is a bispecific antibody that mimics FVIII. It is currently approved for use only in congenital hemophilia A with or without inhibitors, but some clinical experience in patients with AHA has recently been published.

Other potential new non-factor treatments in development for use in congenital hemophilia include anti-tissue factor pathway inhibitor (TFPI) antibodies; inhibition of anti-thrombin (fitusiran), and inhibition of proteins C and S. However, clinical studies of all these therapies in AHA would be required before recommending use. To date, no such clinical studies have been planned.

Key takeaway
Several new and emerging non-factor treatments (including emicizumab, anti-TFPI antibodies, anti-thrombin inhibitors, and inhibitors of protein C and protein S) may offer new treatment options for AHA in the future.

3.10 | Principle 10: Promotion of collaborative research to improve patient outcomes

3.10.1 | Rationale

- As AHA is rare, complex, and most commonly seen in elderly, multimorbid patients, it is one of the most challenging hematologic diseases to treat and many unmet needs and knowledge gaps remain.
- Therefore, every effort should be made to promote international collaborative research to improve our knowledge base and ultimately improve patient outcomes.

3.10.2 | Areas for international collaborative research

Key AHA areas for development include the need for less toxic immunosuppressive regimens and new therapies to treat bleeds. Highly individualized therapy would benefit from collaborative research, where treatment (eg, choice of hemostatic agent, response criteria, immunosuppressive regimen, monitoring schedule, and adjunct medications) are tailored according to the patient’s individual clinical condition.

Currently, the only large-scale data available for AHA are from observational registers and it is vital that further cooperative efforts are made to continue and optimize registry data collection. Outcome data should be regularly and systematically included in registries and should cover long-term follow-up data and detailed information regarding dosing regimens and local clinical practice. Such data would also allow detailed analyses of certain patient subgroups and analyses to identify risk factors for bleeding and/or poor outcomes.

Finally, additional work to further refine the principles outlined in this article is warranted. For instance, these principles were developed by an expert panel of European hemophilia specialists; although principles of care arguably remain the same all over the world, regional or national adaptation of the principles may help to facilitate their implementation in differing healthcare systems and to accommodate cultural and socio-economic diversity, as seen for principles of care developed for congenital hemophilia. Further, input from additional experts in other specialties, such as geriatricians and endocrinologists, would allow greater insights into a more holistic approach for treating AHA. A Delphi process might be useful in this regard.

Key takeaway
International collaborative research is essential to increase knowledge of AHA, enhance data collection in registries, and improve both treatment regimens and management strategies.

4 | CONCLUSIONS

This document sets out key principles for comprehensive, holistic AHA care to ensure swift diagnosis and optimal management, regardless of whether patients present to an HTC or a non-specialist hospital. Key factors in achieving effective holistic care are education and training for healthcare personnel in non-specialist hospitals and collaboration between hemophilia specialists and physicians in other specialties. It is hoped that the proposed principles will increase awareness of AHA in the wider medical community and catalyze renewed efforts and resource contribution toward improving the practical and multidisciplinary treatment of AHA.

ACKNOWLEDGEMENTS

Medical writing and editorial assistance were provided by Julie Smith and Jo Fetterman, Parexel, and funded by a grant from Novo Nordisk. All authors wrote, and directed the development of, the manuscript and take full responsibility for the content and conclusions stated in this manuscript. Novo Nordisk neither influenced the content of this publication nor was it involved in the interpretation.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created in this study.

ORCID
Gerry Dolan https://orcid.org/0000-0003-3270-6932
Cedric Hermans https://orcid.org/0000-0001-5429-8437

REFERENCES
1. Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017;927:695-705.
2. Oldenburg J, Zeitler H, Pavlova A. Genetic markers in acquired hae-mophilia. Haemophilia. 2010;16(Suppl 3):41-45.
3. Collins P, Baudo F, Huth-Kuhne A, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161.
4. Collins P, Baudo F, Knoebel P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120:47-55.

5. Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80:55-63.

6. Huth-Kuene A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94:566-575.

7. Kessler CM, Knoebel P. Acquired haemophilia: an overview for clinical practice. Eur J Haematol. 2015;95(Suppl 1):36-44.

8. Knoebel P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10:622-631.

9. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010;148:183-194.

10. Collins PW. Management of acquired haemophilia A. J Thromb Haemost. 2011;9(Suppl 1):226-235.

11. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109:1870-1877.

12. Tiede A, Giangrande P, Teitel J, et al. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. Haemophilia. 2019;25:969-978.

13. Tiede A, Collins P, Knoebel P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105:1791-1801.

14. Baudo F, Collins P, Huth-Kuene A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120:39-46.

15. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.

16. Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014;40:803-811.

17. Araf S, Aleem S, Liu B, Balikai G. An unusual case of a haemorrhagic stroke: acquired haemophilia A. BMJ Case Rep. 2013;2013.

18. Sumner MJ, Geldziler BD, Pedersen M, Seremets S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13:451-461.

19. Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015;125:1091-1097.

20. Tarantino MD, Cukur A, Hardesty B, Roberts JC, Sholzberg M. Recombinant porcine sequence factor VIII (rFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017;23:101-35.

21. Khan D, Raza-Burton S, Baker P, et al. Acquired hemophilia A treated with recombinant porcine factor VIII: a single centre UK experience. Br J Haematol. 2020;189:e119-e187.

22. Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OB1-1, an antiahaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21:162-170.

23. Turkantoz H, Konigs C, Knoebel P, et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01/2010 Study. J Thromb Haemost. 2020;18:36-43.

24. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIII: a multicentre study. Thromb Haemost. 1997;786:1463-1467.

25. Salah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia. 2004;10:169-173.

26. Novo Nordisk A/S. NovoSeven® Summary of Product Characteristics. https://www.emea.europa.eu/en/documents/product-information/novoseven-epar-product-information_en.pdf. Accessed May 6, 2020.

27. Shire Pharmaceuticals. FEIBA Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/1912/smpc#gref. Accessed October 1, 2020.

28. Pollard DSB, Chowdary P, Gomez K. Use of an innovative syringe pump to deliver bolus rFVIIa for patients with haemophilia and inhibitors undergoing surgery. J Haemophilia Pract. 2018;41:35-39.

29. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160:153-170.

30. Lottenberg R, Kentro TB, Kitchens CS. Acquired haemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987;1476:1077-1081.

31. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;705:753-757.

32. Knoebel P. Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A. Drugs. 2018;78:1861-1872.

33. Holstein K, Liu X, Smith A, et al. Bleeding and response to hemostatic therapy in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2020;136:279-287.

34. Borg JY, Guillett B, Le Cam-Duchez V, et al. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des AutoAntiCorps au cours de l’Hemophilie Acquise) registry. Haemophilia. 2013;194:564-570.

35. Janbain M, Leissinger CA, Kruse-Jarres R. Acquired hemophilia A: emerging treatment options. J Blood Med. 2015;6:143-150.

36. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novoseven Comparative (FENOC) Study. Blood. 2007;109:546-551.

37. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130:2463-2468.

38. European Medicines Agency. Hemlibra Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf. Accessed June 4, 2020.

39. Knoebel P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021;137:410-419.

40. Al-Banai K, Alhillan A, Hawa F, et al. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report. Am J Case Rep. 2019;20:1046-1048.

41. Darse KE, Lindsley JP, Streiff MB, et al. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost. 2019;33:420-423.

42. Hess KJ, Patel P, Joshi AM, Kotkiewicz A. Utilization of Emicizumab in Acquired Factor VIII Deficiency. Am J Case Rep. 2020;21:e922326.

43. Mohrle P, Pekrul I, Spannagl M, et al. Emicizumab in the Treatment of Acquired Haemophilia A: A Case Report. Transfus Med Hemother. 2019;46:121-123.

44. Hartmann J, Croteau SE. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2016;91:1252-1260.

45. Dunkley S, Lam JCM, John MJ, et al. Principles of haemophilia care: the Asia-Pacific perspective. Haemophilia. 2018;24:366-375.

46. Makris M, Kasper C. The World Federation of Hemophilia guideline on management of haemophilia. Haemophilia. 2013;19:1:1.
47. Giangrande P. Acquired Hemophilia: revised version; (2012). World Federation of Hemophilia. http://www1.wfh.org/publications/files/pdf-1186.pdf. Accessed May 06, 2020.
48. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. *Haemophilia*. 2013;191:e1-47.
49. Reding MT, Cooper DL. Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey. *J Multidiscip Healthc*. 2012;5:277-287.

**How to cite this article:** Dolan G, Benson G, Bowyer A, et al. Principles of care for acquired hemophilia. *Eur J Haematol*. 2021;106:762-773. https://doi.org/10.1111/ejh.13592